You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of an electrical impedance myography (EIM) vaginal device for the evaluation of pelvic skeletal muscles
SBC: BOLD TYPE LLC Topic: NICHD1 Abstract2 Bold Type is developing the “SenseWand”, a wireless pelvic floor diagnostic system (device and app)3 to evaluate pelvic floor muscle health using electrical impedance myography (EIM). PFDs are complex4 conditions (e.g. pelvic organ prolapse, stress urinary incontinence, high tone pelvic floor dysfunction) that impact5 millions of women worldwide. It is estimated that PFDs will affe ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Small Molecule MYC Degraders as Novel Cancer Therapeutic Agents
SBC: Stemsynergy Therapeutic Topic: 102PROJECT SUMMARY/ABSTRACT The MYC family proteins are comprised of three paralogs termed c-myc, N-myc, and L-myc. The MYC proteins play a fundamental role in cell proliferation and oncogenesis by regulating cellular processes such as gene transcription, protein translation, cell cycle progression, and cell death. While N-myc and L-myc drive oncogenesis in a small number of cancer types, the require ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Inter-alpha Inhibitors in Experimental Necrotizing Enterocolitis
SBC: PROTHERA BIOLOGICS, INC. Topic: NICHDNecrotizing enterocolitis (NEC) is a devastating acute inflammatory condition of the gastrointestinal tract resulting in intestinal necrosis, systemic sepsis and multi-system organ failure found mostly in infants born prematurely. Despite modern medical advances in the past decade, the etiology remains elusive and morbidity and mortality are still unacceptably high. It has been concluded that the ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension
SBC: AQUALUNG THERAPEUTICS, CORP Topic: NHLBIABSTRACT Pulmonary arterial hypertension (PAH) is a fatal disease (without curative therapies) that is critically influenced by dysregulated inflammatory pathways. This A1 R42 Fast Track STTR application focuses on eNAMPT (extra- cellular nicotinamide phosphoribosyltransferase) as a novel, highly attractive PAH target. Aqualung Therapeutics has developed a humanized eNAMPT-neutralizing mAb, ALT-10 ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy
SBC: STRYKAGEN CORPORATION Topic: 100Abstract Duchenne Muscular Dystrophy (DMD) is a fatal muscle disease with an incidence of 1 in 5000 males. DMD results from mutations in the gene encoding dystrophin, a 427 kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and laminin in the extracellular matrix. The α7β1 integrin is a transmembrane linkage system in skeletal and card ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
A Randomized Phase 2A Clinical Trial Pioneering the Utility of an eNAMPT-Reducing Therapy in ARDS/VILI: the PUERTA Trial
SBC: AQUALUNG THERAPEUTICS, CORP Topic: NHLBIABSTRACT The serious unmet need to address the excessive mortality observed in patients with Acute Respiratory Distress Syndrome (ARDS) has been brought sharply into focus by the current COVID-19 pandemic. In this R-44 application, Aqualung Therapeutics will address this therapeutic gap by utilizing a novel, humanized monoclonal antibody, ALT-100 mAb, which binds/neutralizes a novel ARDS target, e ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury
SBC: PROTHERA BIOLOGICS, INC. Topic: 105Perinatal brain injury resulting in mental retardation and cerebral palsy is the most severe disability in children and affects 40-148 in preterm and 1–2/1000 in full term infants. This places a huge burden on society, emphasizing the critical need for improved prevention/treatment strategies to decrease perinatal brain injury. Hypothermia (HT) is the only FDA approved therapy to attenuate brain ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Protection of transplanted heart function by regulation of Na/K pump activity
SBC: WR Biotech, LLC Topic: NHLBIThe objective of this proposal is to examine a novel technique called improved Synchronization Modulation Electric Field (i-SMEF) in the protection of donor hearts and improvement of transplanted graft functions. We will apply the i-SMEF on donor hearts during static cold storage and evaluate the transplanted graft function following heart transplantation in mice.Heart transplantation (HTx) remain ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Plans4Care: Personalized Dementia Care On-Demand
SBC: Plans4Care INC Topic: RPROJECT ABSTRACT Although rt11 million family/friends are caregivers to rt6 million people with Alzheimer's Disease (AD) and AD- Related Dementias (AD/ADRD), they do not typically receive personalized education, strategies and support to manage their own wellbeing and complex dementia-related symptoms. Lack of personalized care contributes to $321 billion annually in AD/ADRD care costs. In respons ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Interactive Fiction story to teach college readiness executive functioning skills to college-bound students with ASD and ADHD
SBC: OBJECTIVE ED, INC. Topic: 500Project Summary: (30 lines) CTS – College Transition Stories This Phase I SBIR project will determine the feasibility of using an Accessible Interactive Fiction (AIF) story to help students with autism spectrum disorder (ASD), 16 to 21 years old, who are college-bound (CBASD), to improve their ability to succeed in a college environment. Research has shown that practicing college readiness skill ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health